Receptor for Advanced Glycation End Products

AGERprotein

AGER (RAGE) mediates recognition of advanced glycation end products and oxidized lipids, amplifying plaque inflammation and endothelial dysfunction.

Pathway placement

Cascade stepPlaque inflammation

Confidencehigh

RationaleAGE–RAGE axis activates inflammatory pathways; links oxidized lipids to plaque inflammation.

Also acts inLipid entry/oxidation, Endothelial activation/erosion

Druggability

DruggableYes

Known drugs / candidates1

Small-molecule tractableYes

Antibody tractableYes

EnsemblENSG00000204305

Type I vs Type II discrimination

ScoresType-II-associated

R — rupture / Type-I

—

C — confounder / Type-II

A — assay feasibility

E — evidence strength

T1DI (composite)

Specificity differential (R−C)-51.7

Confounder panel (Type-II drivers)

1sepsis / systemic inflammationmag 2

2anemia / acute blood lossn/a

3hypovolemia / dehydrationn/a

4tachyarrhythmiamag 2

5hypoxemia / respiratory failuremag 2

6hypertensive emergencyn/a

7high-demand / peri-operative stressmag 2

Coverage: 4/7 confounders with evidence

Tier: deep-scored (abstract-extracted) · 11 supporting references. See the discrimination table for all markers.

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.

Specimen

Serum or plasma

Collection tube

Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)

Method / principle

Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists

Reagent / substrate

Matched anti-target antibody pair (capture + labeled detection)

Platform

ELISA microplate or multiplex (Luminex/MSD)

Turnaround · availability

Send-out / research · Research-grade (no universal clinical assay)